MedWatch

Lundbeck backs Trintellix with new data

New clinical data from a trial involving Lundbeck's Trintellix in patients with depression and anxiety will put wind in the drug's sails.

Photo: Jens Dresling

A particular group of patients have proven to benefit from being treated with Lundbeck's Trintellix/Brintellix – a group which has otherwise had difficulty finding treatment, according to a Lundbeck press release.

The study contained 100 patients with a primary diagnosis of major depressive disorder (MDD) and a comorbid diagnosis of generalized anxiety disorder (GAD).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs